DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Modified vaccinia Ankara
Modified vaccinia Ankara
Environmental Risk Assessment Deliberate Release of the GMO MVA
Development of a Synthetic Poxvirus-Based SARS-Cov-2 Vaccine
210129 Geovax GV-MVA-VLP™ White Paper
Evaluation of Recombinant Vaccinia Virus—Measles Vaccines in Infant Rhesus Macaques with Preexisting Measles Antibody
Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older:A Randomised Contr
A Vital Gene for Modified Vaccinia Virus Ankara Replication in Human Cells COMMENTARY Gerd Suttera,B,1
Hazard Characterization of Modified Vaccinia Virus Ankara Vector
(MVA) Virus with Continuous Cell Lines
IMVANEX, Modified Vaccinia Ankara Virus
Recombinant Modified Vaccinia Virus Ankara
Fusion of HCV Nonstructural Antigen to MHC Class II–Associated Invariant Chain Enhances T-Cell Responses Induced by Vectored Vaccines in Nonhuman Primates
Modified Vaccinia Virus Ankara (MVA) As Production Platform for Vaccines Against Influenza and Other Viral Respiratory Diseases
Preclinical Development of Hivax: Human Survivin Highly
Skin Delivery of Modified Vaccinia Ankara Viral Vectors Generates Superior T
A Vital Gene for Modified Vaccinia Virus Ankara Replication in Human Cells COMMENTARY Gerd Suttera,B,1
Use of the Regulatory Protein Nef for Vaccination Against HIV-1
Fluorescent Reporter Viruses Identify Non-Plaque-Forming Virions of Vaccinia Virus to Activate Viral Gene Expression
Broad Protection Against Avian Influenza Virus by Using a Modified Vaccinia Ankara Virus Expressing a Mosaic Hemagglutinin Gene
Top View
Immunogenicity and Protection After Vaccination with a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model
Product Information Sheet for NR-727
Viral Vector Manufacturing
Major Article
Clinical Review Memo, September 19, 2019
27Xccpgmvhdzc.Pdf —
Range Gene Contributes to Full Replication of Modified Vaccinia Virus Ankara (MVA) in Human Cells
Human Survivin Highly Immunogenic Vaccines Peter R
Mva Platform Partnership Mva-Bn: Licensed Vaccine Platform
Modified Vaccinia Ankara Based SARS-Cov-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response
Modified Vaccinia Virus Ankara As a Viral Vector for Vaccine Candidates
MVA Agenda: to Review and Evaluate Grant and Resources Research, National Institutes Applications
TH HBV VV-001 Clinical Study
Characterization of Recombinant Modified Vaccinia Virus Ankara for Delivery of Middle East Respiratory Syndrome Coronavirus Spike Protein Antigens
IMVANEX, Common Name
September 24, 2019 Summary Basis for Regulatory Action
Use of Modified Vaccinia Ankara (MVA) for FMDV Vaccination Javier Castillo-Olivares , David Paton, Bryan Charleston, Satya Parida Institute for Animal Health
Package Insert